Global Cancer Immunotherapy Market Outlook 2020

DUBLIN, June 12, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/7vnxrt/global_cancer) has announced the addition of the "Global Cancer Immunotherapy Market Outlook 2020" report to their offering.

Cancer immunotherapies have evolved significantly and numerous products have been introduced in the market. Many cancer immunotherapies are being tested in clinical trials for identification of their pharmacological and commercialization potential. Novel cancer immunotherapies are at different stages of clinical trials which would be introduced in coming years in global market. They could be broadly divided in two classes: specific and non-specific cancer immunotherapy. Basis of this classification is their ability to identify specific antigen related to particular malignancy. Modality used for developing them may be different but all of them will involve the activation of immune system for elimination of cancer. In some cases, overlapping boundaries may be found which is quite possible because single cancer immunotherapy may have multiple effects.

Cancer immunotherapeutics segment seems to be quite dynamic as it has received highly developed products which are absent in other cancer therapeutic category. This category has large number of products belonging to different categories resulting in myriad choices for patients to choose suitable products according to their necessities. They have been able to create dominance in cancer market segment of pharmaceutical industry which is expected to be continued for several years. Some of the products belonging to cancer immunotherapy were introduced few decades ago, while others have received marketing approval in past few years.

Versatility of these cancer immunotherapies allow them to be administrated for different cancer indications due to which their market share is increasing. Different cancer immunotherapy products have different pharmacological profiles due to which some products shows more acceptance rates as compared to other cancer immunotherapies. However, they have superior pharmacological capabilities as compared to their conventional counterparts.

Cancer immunotherapies harbor targeted therapeutics for the treatment of some malignancies. They have been made to target few antigens putatively linked to the cancerous cells. As a result, they have been introduced for limited malignancies due which large unmet medical necessities are observed in this segment. This fact was recognized by pharmaceutical companies and they started to lay emphasis on identification of new biomarkers. Biomarker identification followed by their development is a complex process and requires lots of time. This issue was solved by using knowledge from bioinformatics and allied fields which has been able to save time, investments and precious resources. However, pharmacological and commercialization potential of cancer therapeutics based on novel biomarkers would be known by clinical data.

New modalities, biomarkers and underlying principles are expected to be introduced in global market in coming years. These changes are expected to be propelled by increased fundings and technological advancement in the field of cancer immunotherapeutics. This scenario shows that they are going to play an important role in the treatment of various malignancies. All these facts show that cancer immunotherapies are going to have an optimistic future.

Cancer Immunotherapies Included in Report:

Adoptive Cell Transfer , GM-CSF, Immune Checkpoint Inhibitors, Immunomodulators, Interleukins, Interferon, Monoclonal Antibodies, Vaccines

"Global Cancer Immunotherapy Market Outlook 2020" Report Highlight:

- Introduction & Classification of Cancer Immunotherapy
- Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
- Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
- Global Cancer Immunotherapy Pipeline: 1834 Drugs
- Marketed Cancer Immunotherapies: 113 Drugs
- Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
- Cancer Vaccines Pipeline: 312 Vaccines
- Marketed Cancer mAb: 36 mAb
- Marketed Cancer Vaccines: 12 Vaccines

Key Topics Covered:

1. Introduction to Cancer Immunotherapy

2. Classification of Cancer Immunotherapy

3. Cancer Immunotherapy by Vaccines

4. Cancer Immunotherapy by Monoclonal Antibodies

5. Cancer Immunotherapy by Adoptive Cell Transfer

6. Cancer Immunotherapy by Immune Checkpoint Inhibitors

7. Cancer Immunotherapy by Immunomodulators

8. Cancer Immunotherapy by Cytokines

9. Cancer Immunotherapy by Interleukins

10. Cancer Immunotherapy by Interferon

11. Cancer Immunotherapy by GM-CSF

12. Cancer Immunotherapy Market Overview

13. Global Cancer Immunotherapy Market Dynamics

14. Global Cancer Immunotherapy Market Future Prospects

15. Cancer Cell Therapies Clinical Pipeline by Company, Indication & Phase

16. Marketed Cancer Cell Therapies Drugs Clinical Insight

17. Cancer Cytokines Clinical Pipeline by Company, Indication & Phase

18. Marketed Cancer Cytokines Drugs Clinical Insight

19. Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase

20. Marketed Cancer Immunomodulators Clinical Insight

21. Cancer Vaccine Clinical Pipeline By Company, Indication & Phase

22. Marketed Cancer Vaccines Clinical Insight

23. Cancer Monoclonal Antibodies Clinical Pipeline by Company, Indication & Phase

24. Marketed Cancer Monoclonal Antibodies Drugs Clinical Insight

25. Competitive Landscape

- Abbvie
- Advaxis
- Altor BioScience
- Amgen
- Biogen Idec
- Biogenomics
- Celldex Therapeutics
- Dendreon Corporation
- Eli Lilly
- Expression Genetics
- Galena Biopharma
- Genmab
- Gilead Sciences
- GlaxoSmithKline
- IRX Therapeutics
- ImmunoCellular Therapeutics
- ImmunoGen
- Inovio Pharmaceuticals
- Merck
- NeoStem Oncology
- NewLink Genetics
- Northwest Biotherapeutics
- Novartis
- Peregrine Pharmaceuticals
- Pfizer
- Philogen
- Regulon
- Roche
- Seattle Genetics
- ZymoGenetics

For more information visit http://www.researchandmarkets.com/research/7vnxrt/global_cancer

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets